VCM
IPXL

Versant Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Versant Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,499
Closed -$29K – 1739
2018
Q1 		$29K Sell
1,499
-100
-6% -$1.96K 0.01% 478
2017
Q4 		$26K Sell
1,599
-1,078
-40% -$19.8K 0.01% 551
2017
Q3 		$54K Buy
2,677
+1,248
+87% +$23.9K 0.03% 243
2017
Q2 		$23K Buy
1,429
+1,404
+5,616% +$20.7K 0.01% 546
2017
Q1 		$0 Hold
25
– – ﹤0.01% 1616
2016
Q4 		$0 Sell
25
-63
-72% -$1.08K ﹤0.01% 1618
2016
Q3 		$2K Sell
88
-13
-13% -$349 ﹤0.01% 1237
2016
Q2 		$2K Sell
101
-4
-4% -$130 ﹤0.01% 1202
2016
Q1 		$3K Sell
105
-331
-76% -$11.6K ﹤0.01% 1101
2015
Q4 		$18K Buy
+436
New +$17.4K 0.01% 543

Versant Capital Management's IPXL Position: Q2 2018 in Review

Versant Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 1,499 shares — an estimated $29K sold.

Versant Capital Management first reported a position in IPXL in Q4 2015 and held it in 10 quarters. The position peaked at $54K in Q3 2017. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.

  • Versant Capital Management reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
  • Versant Capital Management sold 1,499 Impax Laboratories, Inc. shares in Q2 2018, an estimated $29K.
  • Versant Capital Management first reported a position in Impax Laboratories, Inc. in Q4 2015 and held it in 10 quarters.
  • Versant Capital Management's Impax Laboratories, Inc. position peaked at $54K in Q3 2017.
  • 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.

Based on Versant Capital Management's 13F filing for Q2 2018, filed 6 Jul 2018.